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ENDOMETRIAL CANCER
Endometrial cancer (EC) is the fourth most com-
mon type of cancer among women and the most com-
mon gynecologic malignancy which accounts for 6% 
of all cancers in females. Lifetime risk in the population 
is about 2%. Since 1960, the number of new cases has 
gradually risen; EC now accounts for 40 % of gyneco-
logical cancers. The mortality rate for EC is 7–10 per 
100,000 women. Obesity, hypertension, physical in-
activity, diabetes, and family history are among the 
most important risk factors for developing EC [1, 2] . 
Thus, EC is one of the growing public health problems.
EC is divided into two pathological subtypes. 
Type 1 endometrioid endometrial carcinomas (EECs) 
account for 80% of all EC, and affects pre- and peri-
menopausal women. Morphologically, Type 1 is an en-
dometrioid cancer. In most cases of Type 1 tumors, 
EC is preceded by hyperplasia that is largely estrogen-
dependent and caused by estrogen simulation that 
is not balanced by progesterone. These tumors are 
usually highly differentiated and have relatively good 
prognosis. Type 2 non-endometrioid endometrial 
carcinomas (NEECs) affects older, postmenopausal 
women whom the non-neoplastic endometrium 
is atrophic. Morphologically these tumors are non-
endometrioid carcinomas and are serous or clear cell 
tumors. Type 2 tumors develop directly from the en-
dometrium without hyperplasia and invade deeply into 
myometrium and follow aggressive clinical courses. 
They are often poorly differentiated and have a worse 
prognosis. Besides the morphological differences, 
Type 1 and Type 2 EC can also distinguished by genetic 
alterations [2, 3, 4] .
MOLECULAR GENETICS 
OF ENDOMETRIAL CANCER
Mutation of PTEN is one the frequent genetic al-
terations in endometroid carcinomas. Approximately 
83% of endometroid carcinomas and 55% of pre-
cancerous lesions (e.g., endometrial intraepithelial 
neoplasia) have shown the alteration of PTEN. PTEN 
tumor suppressor gene is located at chromosome 
10q23, encodes a protein which acts as lipid and pro-
tein phosphatase. PTEN inhibits the PI3K/AKT pathway 
by dephosphorylating PIP3 (product of PI3K). The 
protein phosphatase activity of PTEN is involved in the 
inhibition of focal adhesion formation, migration, and 
inhibition of growth factor-stimulated MAPK signaling. 
Decreased PTEN activity or loss-of-function mutations 
of PTEN causes apoptotic escape and increased cell 
proliferation and survival [2–4].
Other genetic changes in endometroid EC are 
microsatellite instability (MSIS), mutations of K-ras 
and β-catenin genes. Both PTEN and MSIS mutations 
represent an early event in endometrial carcinogen-
esis. PTEN, MSIS and K-Ras mutations often observed 
simulatenously, whereas mutations in β-catenin are 
usually observed alone. β-catenin plays an essential 
role in cell differentiation, organization of the cyto-
skeleton and  acts as transcriptional activator in the 
Wnt signaling pathway [2–4]. K-Ras encodes a mem-
ber of the GTPase family which is involved in signal 
transduction pathways between the nucleus and cell 
surface receptors [2, 4].
P53 mutations are the most frequent changes 
in type 2 EC. The mutated p53 is a non-functional 
protein that often resists degradation, and leads 
to propagation of aberrant cells [3, 4].
Other common genetic alterations of type 2 EC are 
inactivation of p16, overexpression of HER-2/neu and 
reduced expression of E-cadherin [2,3]. Inactivation 
of p16 was found in 45% of serous carcinomas. p16 tu-
mor suppressor gene encodes an inhibitor of CDK, and 
its inactivation leads to uncontrolled cell growth [3]. 
HER2/neu is an oncogene that codes for transmem-
brane tyrosine kinase which activates ErbB signaling 
network and has pro-mitogenic activity [2–4].
Model of endometrial cancer tumorigenesis has 
been defined by presence of these genetic alterations 
in endometroid (Table 1) [4].
Table 1. Pathological characteristic and genetic alteration in type 1 and 
type 2 ECs
Characteristic Type I ( EEC) Type II (NEEC)
Unopposed estrogen Yes No
Background endometrium hyperplastic Atrophic
Morphology Endometrioid Serous, clear cell
Micro satellite instability, % 20–40 0–5
PTEN inactivation, % 50–80 10
K-ras mutations, % 15–30 0–5
B-catenin mutations, % 20–40 0–3
p53 mutations, % 10–20 80–90
HER2/neu, % 10–30 40–80
PI 6 inactivation, % 10 40
E-Cadherin, % 10–20 60–90
Table modified from Bansal N et al. and Doll A et al. [3,4]
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Abbreviations: 2-DE — two-dimensional gel electrophoresis; 
2-DIGE — 2 dimensional differential in-gel electrophoresis; 
EC — endometrial cancer; ECCs — endometrioid endometrial car-
cinomas; HPLC — high-performance liquid chromatography; IEF — 
isoelectrofcousing; MALDI-MSI — matrix-assisted laser desorption 
ionization mass spectrometry imaging; MSI — mass spectrometry 
imaging; MSIS — microsatellite instability; NEECs — non-endome-
trioid endometrial carcinomas; SELDI TOF MS — surface enhanced 
laser desorption/ionization time-of-flight mass spectrometry. 
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ENDOMETRIAL CANCER: CLINICAL 
CONSIDERATIONS
Management of EC in clinic is a challenge, 
as EC ranges from diseases with good prognosis 
to aggressive one with poor outcome [8]. Approxi-
mately 90 % of women at the age of 60 with abnormal 
vaginal bleeding are diagnosed with EC [7]. The cor-
nerstone of EC management is surgical treatment, 
including complete hysterectomy, bilateral salpingo-
oophorectomy, and an appropriate surgical staging. 
In the case of aggressive tumors or advanced disease, 
surgical interventions have to be extended to pelvic 
and para-aortic lymphadenectomy and omentectomy, 
and adjuvant therapy is necessary for patients at high 
risk of recurrence [5, 7]. Postoperative treatment 
may be extended to radiation therapy and sometimes 
to chemotherapy.
However, side-effects from lymphadenectomy in-
clude lymphedema, symptomatic lymphocysts, deep 
vein thrombosis and blood transfusion, whereas side 
effects from whole pelvic irradiation include deleteri-
ous effects on the small and large intestine, urinary 
bladder and vaginal function [5]. Thus, pursuing 
optimal care for women with endometrial cancer, the 
intent is to avoid overtreatment and undertreatment 
by balancing giving adequate therapy while trying 
to minimize treatment side effects [5, 8].
Although the survival rates for patients diagnosed 
with and treated for early stage of EC is good, the 
prognosis of women with advanced stage disease 
or recurrence is  poor (Table 2).
Table 2. Overall survival rates by stage for Type 1 and Type 2 ECs
Endometrioid Non-Endometrioid
Present in earlier stage, % Present with advanced stage, %
Stage I 73 Stage I 54
Stage II 11 Stage II 8
Stage III 13 Stage III 22
Stage IV 3 Stage IV 16
5 year survival rates, % 5 year survival rates, %
Stage I 85–90 Stage I 60
Stage II 70 Stage II 50
Stage III 40–50 Stage III 20
Stage IV 15–20 Stage IV 5–10
Table modified from P.A. Gehrig, V.L. Bae-Jump [9]
For those women with early stage disease, the 
curative therapy is surgery with individualized use 
of volume directed radiotherapy. There is no efficient 
treatment for women with advanced stage disease. 
Commonly these women are treated with combination 
of surgery, chemotherapy and radiation. In the case 
of advanced or recurrent disease, when the surgical 
treatment is not successful, the main therapy has been 
chemotherapy [9].
However, a patient’s risk status can be definitively 
determined only postoperatively. Since certain patho-
logical factors are unavailable or inaccurate, preopera-
tively or intraoperatively, it may be difficult to deter-
mine which patients to select for lymphadenectomy. 
Preoperative histology obtained from endometrial 
biopsy often differs from final pathology [6]. Imaging 
techniques like CT, MRI and PET have poor sensitivity 
and specificity in detecting the depth of myometrial 
invasion, cervical and parametral involvement and 
lymph node metastasis. Therefore understanding 
of the molecular mechanisms of tumorigenesis may 
help to identify molecular markers of EC to customize 
both operative and postoperative treatment [6, 8].
PROTEOMICS OF ENDOMETRIAL CANCER
Discovery of new markers of EC is crucial to clini-
cians, since early detection of the disease and prog-
nosis/diagnosis and monitoring of therapy can in-
crease overall survival and cure rates of the patients. 
During the past two decades, combinations of high-
throughput technologies have exhibited great potential 
in large-scale studies for biomarker discovery [11]. 
Besides more effective clinical therapies and marker-
based screening programs, biomarker identification 
enables diagnosis of the disease at early stages before 
progression to advanced stages [11].
One of the methods of the search for new cancer 
markers is analysis of the expression of tumor proteins 
by proteomics. Proteins are the most common targets 
for diagnosis and treatment of cancer, since proteins 
provide enzymatic reactions, energy production, and 
transmission of information [11].
Proteomics allows comparison of hundreds 
or thousands of proteins to identify disease-specific 
biomarkers. Identification of cancer-related proteins 
is possible because of developments in better sample 
preparation techniques, protein separation, mass 
spectrometry (MS)-based identification, and better 
systemic analysis of proteomics data [10].
The most  frequent  proteomics methods 
used in studies of endometrial diseases include 
“gel-based” proteomics such as two-dimensional gel 
electrophoresis (2-DE) or differential in-gel electro-
phoresis (DIGE). Another technique frequently used 
in this field is surface enhanced laser desorption/
ionization time-of-flight MS (SELDI TOF MS). These 
techniques have been applied with the aim of identify-
ing expressional changes in proteins between normal 
and disease states, or explore molecular mechanism 
involved in tumorigenesis of EC (Figure). Other im-
proved but limited in context “gel-free” proteomics-
base methods are multidimensional protein separation 
technology, quantitative MS-based proteomics and 
matrix-assisted laser desorption ionization MS imag-
ing (MALDI-MSI) [10].
The uses of proteomics-based methods opened 
possibility to build comprehensive proteome profiles 
of patients, and study expression of individual proteins. 
This allows to identify differentially expressed proteins 
that may serve as markers of EC. Performing proteome 
profiling for individual patients opens the possibility 
of personalized treatment [11].
Several proteomics-based studies of EC have been 
reported. In study by Yi et al., role of a COX-2 inhibitor 
on the protein expression in RL95–2 EC cell line was 
evaluated, and showed that expression of COX-2 plays 
an important role in tumorigenesis of EC.  The authors 
showed that COX-2 inhibitor NS-398 inhibited prolif-
eration, viability and invasion of RL95–2 cells. This 
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study  also identified phosphatidylethanolamine bind-
ing protein (PEBP) as upregulated, and heterogeneous 
nuclear ribonucleoprotein K (hnRNP K), α enolase, 
heat shock 70 kDa protein (Hsp70), tropomyosin and 
protein disulﬁde isomerase (PDI) as downregulated 
upon treatment with the inhibitor [12].
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Figure. Proteomics strategies used in studies of EC: Gel-based 
proteomics versus gel-free proteomics. Gel based proteomics 
derives from a traditional protein separation method, such 
as isoelectrofocusing (IEF) and SDS-PAGE, and is based 
on studies of proteins. Gel-free proteomics includes arrays and 
mass spectrometry technologies. MS has progressed to auto-
mated and high-throughput analyses, but is limited to studies 
of peptides or digested protein mixtures. Figure modified from 
H Kuruma et al. [20]
Monge et al. analyzed role of the protein ERM/
ETV5 in myometrial invasion by evaluation of those 
proteins whose expression was changed in endo-
metrial cell lines overexpressing ERM/ETV5 [13]. 
Pathway analysis of differentially expressed proteins 
pointed to actin regulation, transforming growth 
factor-β and progesterone signaling as processes 
regulated by ERM/ETV5. Previously have been re-
ported correlations between deep myometrial invasion 
and more undifferentiated tumors, lyph and vascular 
invasion, node involvement and decreased global 
survival. The study by Monge et al. demonstrated 
that ERM/ETV5 acts with involving matrix metallo-
proteinase-2 to provide the migratory and invasive 
capabilities associated with the switch to myometrial 
inﬁltration [13].
Investigation of the co-expression of survivin, c-
erbB2, and COX-2 in endometrial cancer tissues, and 
evaluation of its prognostic significance in endometrial 
cancer was done in study by Lambropoulou et al. Co-
expression score of c-erbB2, COX-2, and survivin 
in endometrial cancer tissues correlates significantly 
with  classical clinico-pathological parameters and 
most importantly to the survival rate of endometrial 
cancer patients. Obtained data helped in understand-
ing of the tumorigenesis in EC, and application of ther-
apeutic strategies such as Cox-2 inhibition or silencing 
of survivin [14].
Maxwell et al. [18] described proteome analysis 
of stage I endometrial cancer tissue, and identified 
proteins associated with oxidative processes and in-
flammation. Changes in oxidative processes indicate 
mitochondrial dysfunction that is one the hallmarks 
of carcinogenesis.  A number of evidences show sig-
nificant increases in acidosis and hypoxia in the tissue 
microenvironment even at the earliest stages of car-
cinomas. One of the requirements of tumor cells for 
progression and proliferation is to acquire and maintain 
increased levels of hypoxia and acidosis. Identified 
by Maxwell et al. [18] overexpressed peroxiredoxin 
family proteins support this notion.
Many novel markers, such as CD171, PTEN, uro-
kinase plasminogen activator receptor have been 
identified and applied in diagnostic and prognostic 
of EC. Other potential markers include Cyclophilin 
A that is involved in early carcinogenesis but not 
in advanced invasion or metastasis. Epidermal fatty 
acid-binding protein (E-FABP) contributes to carci-
nogenesis and metastasis by regulating differentia-
tion and cell growth. Calcyphosine (CAPS) is a major 
phosphorylated substrate of cAMP-depentent protein 
kinase involved in the coordination of cell proliferation 
and differentiation [15–19]. Thus, proteomics stud-
ies delivered a number of potential markers that may 
improve diagnostic and prognostic of EC. However, 
application of proteomics to EC has only been started, 
and more potential markers are expected.
FUTURE PERSPECTIVE
Oncoproteomics is the growing fields which aimed 
to explore the mechanisms involved in carcinogenesis. 
In recent years, discovery of cancer markers by ap-
plication of proteomic approaches has been a fast 
developing area. Identification of biomarkers with high 
sensitivity and specificity would reduce the incidence 
and mortality rate from EC, promote screening and 
enable better choice of treatment for EC patients [11].
Attempts have been made to gain insights into 
endometrial tumorigenesis via studies of proteins 
which change their expression in tumors as compared 
to normal endometrium. Accurate validation of these 
potential biomarkers into clinically relevant, diagnos-
tic and prognostic tools is needed. Analysis of large 
number of samples and adequate statistical testing 
are essential for further progress [10].
Despite many EC-related proteins have been iden-
tified, proteomics of endometrial cancers is poorly 
developed. Currently, no biomarker exists in clinical 
practice for the detection of early stage or aggressive 
EC. Diagnosis therefore relies on the presence of gen-
eral symptoms, which are not present in all patients. 
The expectation is that expansion of proteomics stud-
ies of EC will provide sufficient number of EC-related 
proteins to build proteome signatures for clinical use.
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